Novo Nordisk stock remains in a strong downtrend, trading below key moving averages ahead of Q4 earnings. Analysts maintain a bullish outlook, with a consensus price target of $116.57, implying a ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...

Novo Nordisk reported DKK 85.7B in net sales for Q4, marking ~30% YoY growth on a currency-adjusted basis, expanding its full-year net sales by ~26% YoY to DKK 290.4B on the same basis.

In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two companies have approved weight loss drugs that are generating billions ...

Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The company’s GLP-1 drugs ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. Get access to the leaderboards ...

Sept 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected ...

Novo Nordisk's profit of DKK28.23 billion also topped estimates. Wegovy sales soared 107% at constant exchange rates to DKK19.87 billion, just below estimates. Ozempic sales rose 12% to DKK33.85 ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force behind its strong numbers. It may not be long before Novo Nordisk also ...